

Mara Serena Serafini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2008713/publications.pdf>

Version: 2024-02-01

11
papers

119
citations

1478280

6
h-index

1372474

10
g-index

11
all docs

11
docs citations

11
times ranked

261
citing authors

#	ARTICLE	IF	CITATIONS
1	Mining of Self-Organizing Map Gene-Expression Portraits Reveals Prognostic Stratification of HPV-Positive Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2019, 11, 1057.	1.7	25
2	Transcriptomics and Epigenomics in head and neck cancer: available repositories and molecular signatures. <i>Cancers of the Head & Neck</i> , 2020, 5, 2.	6.2	22
3	Development of a multiomics database for personalized prognostic forecasting in head and neck cancer: The Big Data to Decide <scp>EU</scp> Project. <i>Head and Neck</i> , 2021, 43, 601-612.	0.9	18
4	Gene Expression Clustering and Selected Head and Neck Cancer Gene Signatures Highlight Risk Probability Differences in Oral Premalignant Lesions. <i>Cells</i> , 2020, 9, 1828.	1.8	13
5	A functional gene expression analysis in epithelial sinonasal cancer: Biology and clinical relevance behind three histological subtypes. <i>Oral Oncology</i> , 2019, 90, 94-101.	0.8	12
6	Tumor Biomarkers for the Prediction of Distant Metastasis in Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2020, 12, 922.	1.7	12
7	Clinical Validity of a Prognostic Gene Expression Cluster-Based Model in Human Papillomavirus-Positive Oropharyngeal Carcinoma. <i>JCO Precision Oncology</i> , 2021, 5, 1666-1676.	1.5	6
8	Immunotherapy for the prevention of high-risk oral disorders malignant transformation: the IMPEDE trial. <i>BMC Cancer</i> , 2021, 21, 561.	1.1	5
9	Complete Response to Nivolumab in Recurrent/Metastatic HPV-Positive Head and Neck Squamous Cell Carcinoma Patient After Progressive Multifocal Leukoencephalopathy: A Case Report. <i>Frontiers in Oncology</i> , 2021, 11, 799453.	1.3	5
10	Biological properties of hypoxia-related gene expression models/signatures on clinical benefit of anti-EGFR treatment in two head and neck cancer window-of-opportunity trials. <i>Oral Oncology</i> , 2022, 126, 105756.	0.8	1
11	Co-existence of KRAS and LKB1 mutation as predictor of resistance to Erlotinib: Customized next-generation sequencing (NGS) of TAILOR trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, e20631-e20631.	0.8	0